MediPharm Labs announces listing on the Frankfurt Stock Exchange
TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) - MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (FSE: MLZ) ("MediPharm"), a leader in specialized, research-led cannabis production, distillation, purification and cannabinoid isolation, is pleased to announce that its Ordinary shares are now listed on the Frankfurt Stock Exchange (FSE) under the ticker symbol "MLZ". The Company is also listed on the Toronto Stock Exchange (TSXV) under the ticker symbol "LABS" and on the OTC in the US under the ticker symbol "MLCPF".
"Listing on the Frankfurt Stock Exchange is an important step in our future growth as we focus on both domestic and international opportunities. In addition, MediPharm will be even more visible to the global investor community, "
said Patrick McCutcheon, MediPharm's Chief Executive Officer.
"Now that investor interest in and momentum in the cannabis industry continues to grow, our company is well positioned to participate in the European and global cannabis markets as they continue to expand and we receive our EU GMP certification that makes it possible that products from MediPharm can be exported all over Europe. "
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs is the first Canadian producer of cannabis oil under the Canadian ACMPR Regulation without first obtaining a license to grow cannabis. This specialist focus on cannabis concentrates from our clean rooms, which meet cGMP (current good manufacturing practices) and ISO standards, and our lab, which meets the requirements for critical environments, allows MediPharm Labs, purified pharmaceutical grade cannabis oil and concentrates, to be advanced produce derivative products. MediPharm Labs has invested in a competent, research-driven team, state-of-the-art technology, downstream extraction methods and dedicated production facilities to help patients and consumers deliver safe and precisely dosed cannabis products. MediPharm Labs' private label program is a high margin business for the Company, which opportunistically procures dry cannabis flowers and blends from its many product supply partners to produce proprietary cannabis oil concentrate products for worldwide resale under private label. MediPharm Labs recently joined the Canadian Cannabis AwardsSTARTUP COMPANY OF THE YEAR NAMED . About the subsidiary MediPharm Labs Australia Pty. Ltd. MediPharm has also completed the process of obtaining and importing medicinal cannabis products in Australia from the Australian Federal Office for Drug Control.
For more information, please contact:
Laura Lepore, Vice President, Investor Relations & Communications
Phone: 705-719-7425, ext. 216
E-mail: investors@medipharmlabs.com
Website: www.medipharmlabs.com
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS DEFINED IN THIS TERMS IN THE TERMS OF THE TSX VENTURE EXCHANGE) ASSUMES RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.
IMPORTANT NOTE ON FUTURE-ORIENTED INFORMATION:
This press release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") as defined by applicable Canadian securities laws. All statements other than statements of historical fact are forward-looking statements and based on expectations, estimates and forecasts at the time of this press release. Any statement that includes discussions about predictions, expectations, beliefs, plans, forecasts, goals, assumptions, future events, or performance (often, but not always, using terms such as "expects" or "does not expect," is expected "," Foresees "or" does not anticipate "," plans "," budget "," planned "," predicts "," estimates "," believes "or" intended "or variations of such words and phrases or statement . that certain acts, events, or results may occur or be achieved, "could," "might," "possibly," or "may") are not statements of historical fact and may be forward-looking statements. Forward-looking statements in this press release include expected participation in European and global cannabis markets, expected GMP certification and commencement of operations in Australia. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors that may cause that actual results and future events materially differ from those results or events expressed or implied by such forward-looking statements. These factors include, but are not limited to, general business, economic, competitive, political and social uncertainties, MediPharm's inability to obtain adequate funding, and the delay or failure to obtain regulatory approvals. No assurance can be given that such statements will prove to be accurate, as actual results and future events may differ materially from those anticipated in these statements. Accordingly, readers should not rely on the forward-looking statements and information contained in this press release. Subject to applicable law, MediPharm assumes no obligation to update any forward-looking statements about beliefs, opinions, prognoses or other factors as they change.
